Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Octomom’s fertility specialist loses license

A Beverly Hills fertility doctor who assisted Nadya Suleman in conceiving octuplets is set to lose his medical license, the Medical Board of California announced Wednesday.

2 Jun 2011

Women with ovarian cancer could benefit from new targeted testing

Women with ovarian cancer could be helped by a new test that identifies the specific type of tumour they have, a conference will hear this week.

1 Jun 2011

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Two of Almac's main research projects have been selected for presentation at the 2011 ASCO meeting. Both of these studies are based on Almac's approach of profiling large clinical datasets and analysing the data for molecular subgroups that can aid in improved diagnosis of cancer by identifying molecular subtypes and by identifying molecular subgroups which are of clinical and therapeutic relevance.

31 May 2011

Canadian women more aware of ovarian cancer now, but misconceptions remain

Canadian women know more about ovarian cancer than they did six years ago, but misconceptions remain that could lead to late diagnosis of the country's most fatal gynecologic cancer - a disease that claims the lives of 70% of those diagnosed.

30 May 2011

New insights into pathogenesis and treatment of hereditary breast, ovarian cancer

5% to 10% of all breast cancers are monogenic in origin. In other words, there is a mutation of the genes BRCA1, BRCA2 or other high-risk genes. In this edition of Deutsches Ärzteblatt International, Alfons Meindl of the Klinikum rechts der Isar and coauthors report on new insights into the pathogenesis and treatment of hereditary breast and ovarian cancer and newly-discovered risk genes.

30 May 2011

OVA1 more effective than CA 125 test in evaluating likelihood of ovarian cancer

A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than a physician's preoperative assessment alone.

From Quest Diagnostics 27 May 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.

26 May 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.

26 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Variant of obesity gene may increase breast cancer risk

New research aimed to better identify the genetic factors that lead to breast cancer has uncovered a link between the fat mass and obesity associated gene and a higher incidence of breast cancer.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

AstraZeneca announced today encouraging results from a phase II study in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) who had received maintenance treatment with the investigational drug olaparib, after the completion of chemotherapy.

19 May 2011

APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Gemcitabine HCI for Injection, USP, in the 2 g dosage strength. APP will launch this presentation of Gemcitabine immediately.

19 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

EntreMed reports net loss of $2.6 million for first quarter 2011

EntreMed, Inc., a clinical-stage pharmaceutical company, today announced financial results for the three months ended March 31, 2011.

16 May 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).

16 May 2011

Study: OVA1 blood test can accurately predict ovarian cancer in women with pelvic masses

A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology guidelines for determining the likelihood that an ovarian mass is cancerous prior to surgery would accurately identify more women with ovarian cancer if the OVA1 blood test were used in place of the currently recommended CA 125 blood test.

From Quest Diagnostics 13 May 2011

Researchers help explain why smart drugs are not effective in some cancer patients

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor, and found that a decoy receptor might be limiting the amount of drug that gets to the intended target.

12 May 2011

Swedish adds new virtual reality training simulator to help surgeons practice on robotic-assisted system

As one of the first medical centers in the Northwest to perform robotic-assisted surgery, Swedish is home to the fastest growing, most comprehensive and experienced robotic-assisted surgical program in the region. Swedish established the multidisciplinary, robotic-assisted surgical program in 2005 and has since performed more than 3,400 robotic-assisted surgeries -- more than any other program in the region.

12 May 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Octomom’s fertility specialist loses license

Women with ovarian cancer could benefit from new targeted testing

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Canadian women more aware of ovarian cancer now, but misconceptions remain

New insights into pathogenesis and treatment of hereditary breast, ovarian cancer

OVA1 more effective than CA 125 test in evaluating likelihood of ovarian cancer

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Variant of obesity gene may increase breast cancer risk

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

EntreMed reports net loss of $2.6 million for first quarter 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Study: OVA1 blood test can accurately predict ovarian cancer in women with pelvic masses

Researchers help explain why smart drugs are not effective in some cancer patients

Swedish adds new virtual reality training simulator to help surgeons practice on robotic-assisted system

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in